Evidence map›Paper›PMID 41564125›Full record

ArticleProceedings of the National Academy of Sciences of the United States of America2026

Selective targeting of NRF2-high pancreatic ductal adenocarcinoma with an NQO1-activatable prodrug.

Laura Antonucci, Kosuke Watari, Yechen Feng, Jingjing Qi, Mandy Zhu, Tingya Wang, Isabella Ng, Emily A Vucic, Irene Riahi, Li Huang and 12 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Proceedings of the National Academy of Sciences of the United States of America, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

22 authors.

Laura AntonucciDepartment of Pharmacology, Laboratory of Gene Regulation and Signal Transduction, University of California San Diego School of Medicine, La Jolla, CA 92093.ORCID 0000-0002-3659-7334
Kosuke WatariDepartment of Pharmacology, Laboratory of Gene Regulation and Signal Transduction, University of California San Diego School of Medicine, La Jolla, CA 92093.ORCID 0000-0003-0260-2323
Yechen FengDepartment of Pharmacology, Laboratory of Gene Regulation and Signal Transduction, University of California San Diego School of Medicine, La Jolla, CA 92093.
Jingjing QiDepartment of Pharmacology, Laboratory of Gene Regulation and Signal Transduction, University of California San Diego School of Medicine, La Jolla, CA 92093.
Mandy ZhuDepartment of Pharmacology, Laboratory of Gene Regulation and Signal Transduction, University of California San Diego School of Medicine, La Jolla, CA 92093.
Tingya WangDepartment of Oncology, Zhongda Hospital, Southeast University, Nanjing 210009, China.
Isabella NgMoores Cancer Center, University of California San Diego, La Jolla, CA 92037.
Emily A VucicDepartment of Biochemistry and Molecular Pharmacology, New York University School of Medicine, New York, NY 10016.
Irene RiahiDepartment of Pathology, Jonsson Cancer Center, University of California Los Angeles David Geffen School of Medicine Los Angeles, CA 90095.
Li HuangDepartment of Laboratory Medicine, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310000, China.
Mojgan HosseiniDepartment of Pathology, University of California San Diego School of Medicine, La Jolla, CA 92093.
Evangeline MoseDepartment of Surgery, University of California San Diego School of Medicine, La Jolla, CA 92093.
Randall FrenchDepartment of Surgery, University of California San Diego School of Medicine, La Jolla, CA 92093.
Jonathan WeitzDepartment of Surgery, University of California San Diego School of Medicine, La Jolla, CA 92093.
Dafna Bar-SagiDepartment of Biochemistry and Molecular Pharmacology, New York University School of Medicine, New York, NY 10016.
David W DawsonDepartment of Pathology, Jonsson Cancer Center, University of California Los Angeles David Geffen School of Medicine Los Angeles, CA 90095.ORCID 0000-0002-0215-5861
Beicheng SunDepartment of Hepatobiliary Surgery, The Affiliated Drum Tower Hospital of Nanjing University Medical School, Nanjing 210008, China.
Herve TiriacMoores Cancer Center, University of California San Diego, La Jolla, CA 92037.
Jinyi XuState Key Laboratory of Natural Medicines and Department of Medicinal Chemistry, China Pharmaceutical University, Nanjing 210009, China.
Shengtao XuState Key Laboratory of Natural Medicines and Department of Medicinal Chemistry, China Pharmaceutical University, Nanjing 210009, China.
Andrew M LowyDepartment of Surgery, University of California San Diego School of Medicine, La Jolla, CA 92093.
Michael KarinDepartment of Pharmacology, Laboratory of Gene Regulation and Signal Transduction, University of California San Diego School of Medicine, La Jolla, CA 92093.ORCID 0000-0002-2758-6473

Funding

VIRAL MALIGNANCYP30CA023100 · NCI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI DIANE M SIMEONE · 1985 to 2026
$124.9M
The effect of cancer cell produced collagen 1 homotrimers on DDR1 signaling activation by microenvironmental collagen 1 fragments.U01CA274295 · NCI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI Michael Karin, ANDREW M LOWY · 2022 to 2026
$5.2M
Role of Inflammation in tumor promotion and progressionR01CA118165 · NCI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI KARIN, MICHAEL · 2007 to 2016
$4.6M
Role of p62/SQSTM1 in obesity-induced liver cancerR01CA211794 · NCI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI KARIN, MICHAEL, MOSCAT, JORGE · 2017 to 2021
$3.6M
RON Receptor in Pancreatic Cancer Biology and TherapyR01CA155620 · NCI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI LOWY, ANDREW M · 2011 to 2021
$2.9M
A co-infection model for papillomavirus associated infections and cancersR21CA274265 · NCI · PENNSYLVANIA STATE UNIV HERSHEY MED CTR · PI GILBERT, NICOLE MARIE, HU, JIAFEN · 2023 to 2024
$433k
NCI NIH HHS P30 CA023100NCI NIH HHS R01 CA118165NCI NIH HHS R01 CA155620NCI NIH HHS R01 CA211794NCI NIH HHS R21 CA274265NCI NIH HHS U01 CA274295
6 · The paper itself

Abstract

Activation of transcription factor NRF2 in pancreatic ductal adenocarcinoma (PDAC) promotes aggressive tumor phenotype and protection from therapy-induced oxidative stress. We postulated that NRF2

Indexed as

Carcinoma, Pancreatic DuctalNAD(P)H Dehydrogenase (Quinone)NF-E2-Related Factor 2Pancreatic NeoplasmsProdrugsAnimalsCell Line, TumorDeoxycytidineFemaleGemcitabineHumansMiceMice, Inbred C57BLDeoxycytidineGemcitabineNAD(P)H Dehydrogenase (Quinone)NFE2L2 protein, humanNF-E2-Related Factor 2NQO1 protein, humanNqo1 protein, mouseProdrugsNQO1PDACprodrugs

Identifiers

PMID41564125
PMCPMC12849708

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.